Compare JRSH & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JRSH | CGTX |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 79.6M |
| IPO Year | 2017 | 2021 |
| Metric | JRSH | CGTX |
|---|---|---|
| Price | $5.47 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $4.00 | $3.33 |
| AVG Volume (30 Days) | 100.6K | ★ 483.6K |
| Earning Date | 02-09-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.68% | N/A |
| EPS Growth | ★ 485.71 | 62.79 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $166,263,870.00 | N/A |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | $41.92 | ★ N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $2.85 | $0.55 |
| 52 Week High | $5.81 | $2.26 |
| Indicator | JRSH | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 52.33 |
| Support Level | $3.01 | $1.02 |
| Resistance Level | $5.47 | $1.18 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 29.41 | 73.32 |
Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).